📊 ATOS Key Takeaways
Is Atossa Therapeutics, Inc.. (ATOS) a Good Investment?
Atossa Therapeutics is a pre-revenue pharmaceutical company with severe cash burn and negative returns on equity and assets, indicating value destruction. While the company maintains a strong cash position of $51.8M, at a quarterly burn rate of $19.2M in operating cash flow, the runway extends only ~2.7 years without revenue generation. The complete absence of revenue combined with mounting operating losses makes this a high-risk early-stage biotech with unproven commercial viability.
Atossa Therapeutics has a strong balance sheet with $51.84M of cash, no long-term debt, and very high liquidity, which supports continued clinical development without immediate financing pressure. However, the business remains pre-revenue and deeply unprofitable, with negative operating cash flow and no evidence yet of self-sustaining growth, so the fundamentals are financially stable but operationally speculative.
Why Buy Atossa Therapeutics, Inc.. Stock? ATOS Key Strengths
- Strong liquidity position with $51.8M in cash and 6.77x current ratio providing runway for continued R&D
- Minimal debt burden with zero long-term debt and 0.00x debt-to-equity ratio reducing financial distress risk
- Operating expenses remain controlled relative to cash reserves, suggesting disciplined cash management
- Very strong liquidity with a 6.77x current and quick ratio
- Debt-free balance sheet with $49.79M of equity and no long-term debt
- Cash reserves cover multiple years of current operating cash burn
ATOS Stock Risks: Atossa Therapeutics, Inc.. Investment Risks
- Zero revenue with $25.7M quarterly operating losses indicates pre-commercial stage with unproven product-market fit
- Negative FCF of $19.2M per quarter limits R&D spending flexibility and creates near-term existential risk if funding unavailable
- Severely negative ROE (-47.9%) and ROA (-41.1%) demonstrate substantial shareholder value destruction and capital inefficiency
- Cash runway of approximately 2.7 years creates near-term dilution risk if additional capital raises required before achieving profitability
- Zero revenue means the business is entirely dependent on external capital and pipeline progress
- Persistent operating and net losses indicate weak profitability with no near-term earnings support
- Negative free cash flow and high cash burn could force dilution if development timelines extend
Key Metrics to Watch
- Quarterly operating cash burn rate trend and runway to profitability/next capital raise
- Clinical trial progression and regulatory milestone achievements for pipeline drugs
- Cash balance preservation and any equity or debt financing announcements
- Quarterly operating cash burn relative to the $51.84M cash balance
- Any transition from zero revenue toward licensing, collaboration, or product revenue
Atossa Therapeutics, Inc.. (ATOS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.77x current ratio provides a solid financial cushion.
ATOS Profit Margin, ROE & Profitability Analysis
ATOS vs Healthcare Sector: How Atossa Therapeutics, Inc.. Compares
How Atossa Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Atossa Therapeutics, Inc.. Stock Overvalued? ATOS Valuation Analysis 2026
Based on fundamental analysis, Atossa Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Atossa Therapeutics, Inc.. Balance Sheet: ATOS Debt, Cash & Liquidity
ATOS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Atossa Therapeutics, Inc..'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-3.04 indicates the company is currently unprofitable.
ATOS Revenue Growth, EPS Growth & YoY Performance
ATOS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2016 | N/A | $204.7K | N/A |
| Q2 2016 | N/A | -$1.7M | N/A |
| Q1 2016 | N/A | -$2.3M | N/A |
| Q3 2015 | $3.4K | -$3.2M | N/A |
| Q2 2015 | $9.9K | -$3.1M | N/A |
| Q1 2015 | N/A | -$2.4M | N/A |
| Q3 2014 | N/A | -$3.2M | N/A |
| Q2 2014 | N/A | -$2.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Atossa Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
ATOS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Atossa Therapeutics, Inc.. (CIK: 0001488039)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATOS
What is the AI rating for ATOS?
Atossa Therapeutics, Inc.. (ATOS) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 81% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATOS's key strengths?
Claude: Strong liquidity position with $51.8M in cash and 6.77x current ratio providing runway for continued R&D. Minimal debt burden with zero long-term debt and 0.00x debt-to-equity ratio reducing financial distress risk. ChatGPT: Very strong liquidity with a 6.77x current and quick ratio. Debt-free balance sheet with $49.79M of equity and no long-term debt.
What are the risks of investing in ATOS?
Claude: Zero revenue with $25.7M quarterly operating losses indicates pre-commercial stage with unproven product-market fit. Negative FCF of $19.2M per quarter limits R&D spending flexibility and creates near-term existential risk if funding unavailable. ChatGPT: Zero revenue means the business is entirely dependent on external capital and pipeline progress. Persistent operating and net losses indicate weak profitability with no near-term earnings support.
What is ATOS's revenue and growth?
Atossa Therapeutics, Inc.. reported revenue of $0.0.
Does ATOS pay dividends?
Atossa Therapeutics, Inc.. does not currently pay dividends.
Where can I find ATOS SEC filings?
Official SEC filings for Atossa Therapeutics, Inc.. (CIK: 0001488039) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATOS's EPS?
Atossa Therapeutics, Inc.. has a diluted EPS of $-0.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ATOS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Atossa Therapeutics, Inc.. has a SELL rating with 81% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ATOS stock overvalued or undervalued?
Valuation metrics for ATOS: ROE of -47.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ATOS stock in 2026?
Our dual AI analysis gives Atossa Therapeutics, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ATOS's free cash flow?
Atossa Therapeutics, Inc..'s operating cash flow is $-19.2M, with capital expenditures of $16.0K.
How does ATOS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -47.9% (avg: 15%), current ratio 6.77 (avg: 2).